Zofran Lawsuit 2026: All 430 Cases Dismissed — What Happened, the $453,989 Costs Order & What's Left
The federal Zofran birth-defect litigation is over. In June 2021, a judge dismissed all 430 cases on federal preemption, ruling the FDA was fully informed about Zofran and had repeatedly refused pregnancy warnings. The appeals court affirmed in January 2023, and in February 2024 the plaintiffs were ordered to pay GlaxoSmithKline $453,989 in costs. No verdict or settlement was reached.
Key facts
- Zofran (ondansetron) was FDA-approved in 1991 for nausea from chemotherapy, radiation, and surgery — never for pregnancy nausea, though widely prescribed off-label for morning sickness.
- MDL No. 2657, In re: Zofran (Ondansetron) Products Liability Litigation, consolidated more than 430 cases before Judge F. Dennis Saylor IV in the District of Massachusetts.
- On June 1, 2021, the court granted summary judgment for GSK on federal preemption, finding the FDA was "fully informed" and had "repeatedly refused" the warnings plaintiffs sought.
- On January 9, 2023, the First Circuit affirmed; in February 2024, plaintiffs were ordered to pay GSK $453,989 in costs, including $429,104 for medical records.
- As of October 2026: no verdicts, no settlements, no new developments — and no attorneys are known to be taking new Zofran cases.
For plain-English video briefings on money and law topics, subscribe to Problem Solved.
What Zofran Is — and What It Was Never Approved For
Zofran is the brand name for ondansetron, an antiemetic — a drug that prevents or treats nausea and vomiting. The FDA approved it in 1991 for chemotherapy and radiation patients and for post-operative nausea. It was not approved, and has never been approved, for nausea in pregnancy — yet doctors prescribed it off-label for years, making it one of the most common drugs for morning sickness. The FDA's label acknowledges that studies on birth defects show inconsistent results. Plaintiffs alleged the off-label use was driven by unlawful promotion by the manufacturer, a claim the courts never reached: the cases were decided on preemption before the marketing evidence was weighed. Our earlier Zofran birth defect lawsuit explainer covers who filed and what the original claims said.
How 430 Lawsuits Became One Federal Case
The lawsuits told similar stories: mothers who took Zofran in the first trimester alleged children born with defects including transposition of the great vessels, atrial and ventricular septal defects, cleft lip and palate, kidney defects, and clubfoot. Beginning in 2015, the federal cases were consolidated into MDL No. 2657 — a multidistrict litigation, the procedure gathering similar federal lawsuits before one judge. The MDL grew past 430 cases, and the court set a first bellwether trial — a representative test case guiding settlement talks — for October 2021. It never happened: in a 68-page order on June 1, 2021, Judge Saylor ended the entire MDL in a single ruling.
Federal Preemption: The Doctrine That Ended Everything
Federal preemption is the rule that federal law overrides conflicting state law. The plaintiffs sued under state law, arguing GSK should have added birth-defect warnings to Zofran's label. GSK's defense: only the FDA controls prescription-drug labeling, and the FDA had reviewed Zofran's pregnancy data repeatedly without requiring such warnings — so a state-law warning would have meant violating federal law. The court agreed. The decisive backdrop was the Supreme Court's 2019 decision in Merck v. Albrecht, holding that judges — not juries — decide preemption. Judge Saylor had denied GSK's preemption motion in 2019, sending the question toward a jury; after Albrecht, he reconsidered, found "clear evidence" the FDA would have rejected the proposed warning, and granted summary judgment. In January 2023, the First Circuit affirmed: federal law preempted the state claims.
The $453,989 Costs Order
In February 2024, Judge Saylor ordered the plaintiffs to pay GlaxoSmithKline $453,989 in litigation costs — a documented figure for this named case. Of that total, $429,104 covered obtaining medical records for 437 individual plaintiffs. The judge called gathering those records a basic obligation of competent defense work and rejected requests for individualized financial-hardship hearings, allocating the obligations equally among the plaintiffs. For families who had already lost their cases, the order was a final, painful coda: the losing side in federal litigation can be required to pay the winner's taxable costs. It is one more reason experienced attorneys weigh the strength of the legal theory — not just the sympathy of the facts — before filing.
Can You Still File a Zofran Claim in 2026?
The honest answer is that there is effectively no path left. The federal MDL is closed, and any new federal claim would run into the preemption ruling that ended the last 430. State-court filings face the same defense plus statutes of limitations — the legal deadlines for suing — which for most potential plaintiffs expired years ago, though rules pausing the clock for minors can extend them in some states. As of October 2026, legal publisher Drugwatch reported no new developments and said it was unaware of any attorneys taking Zofran cases. That does not make filing impossible in every circumstance, and an attorney can evaluate your facts — but no one should spend money or energy assuming a new Zofran case has realistic prospects. If your concern is a different drug, the landscape differs: the Depo-Provera litigation reached a settlement with a filing deadline, and our Essure deadlines guide explains filing windows in a live mass tort.
The Lesson for Every Drug-Injury Case
The Zofran litigation is a case study taught the hardest way: even sympathetic facts lose when the legal theory cannot survive. Preemption is the quiet killer of drug-injury claims — when the FDA has reviewed the exact safety question and declined to require a warning, state-law failure-to-warn claims face a battle few survive. For anyone evaluating a drug-injury claim today, the Zofran story supplies the right first question — not "how badly was someone hurt," but "what did the FDA actually decide, and when." Ask it early, with an attorney who has faced preemption defenses before, and you will save yourself years.
Who Benefits From This — and Who Does Not
Who benefits most from this guide:
Readers deciding whether to spend anything on a Zofran claim How: there is no active federal Zofran litigation, and as of October 2026 no attorneys are known to be taking new Zofran cases, so this guide's honest answer saves wasted money and energy
People whose facts might still fit a remaining state-law option How: an attorney can review your facts for any remaining state-law option, since rules pausing the clock for minors can extend deadlines in some states, even though realistic prospects are minimal
People with a claim about a different drug How: the landscape differs by drug: the Depo-Provera litigation reached a settlement with a filing deadline, and other live mass torts still accept cases
Who does not benefit:
Anyone expecting a Zofran settlement or trial How: no Zofran birth-defect case went to trial and no settlement was ever reached, and all 430 federal cases were dismissed with no plaintiff receiving compensation
Anyone planning a new federal claim How: any new federal claim would run into the preemption ruling that ended the last 430 cases, affirmed by the First Circuit in January 2023
Anyone assuming old filing deadlines are still open How: for most potential plaintiffs the statutes of limitations expired years ago, and state-court filings face the same preemption defense
For filing windows in a live mass tort, see our Essure deadlines guide.
Frequently Asked Questions
Was there ever a Zofran settlement?
No. No Zofran birth-defect case went to trial and no settlement was ever reached. All 430 federal cases were dismissed, and no plaintiff received compensation.
Why were the Zofran cases dismissed?
On federal preemption. The court found the FDA was fully informed about Zofran's safety data and had repeatedly refused to require pregnancy warnings, so the state-law claims demanding those warnings were barred by federal law. The First Circuit affirmed in January 2023.
Can I join a Zofran lawsuit in 2026?
There is no active federal Zofran litigation, and as of October 2026 no attorneys are known to be taking new Zofran cases. A lawyer can review your facts for any remaining state-law option, but realistic prospects are minimal.
Is Zofran still prescribed during pregnancy?
Doctors may still prescribe it off-label for severe nausea. The FDA has never approved Zofran for morning sickness, and its label states that studies on birth defects show inconsistent results.
This article is general information, not legal, medical, or financial advice. Court proceedings evolve — consult a qualified attorney about your own situation before acting.
Who benefits from this Zofran guide, and who does not?
Readers deciding whether to spend anything on a Zofran claim benefit most, because the honest answer is that there is effectively no path left: no case went to trial, no settlement was ever reached, and all 430 federal cases were dismissed. People expecting a Zofran settlement, planning a new federal claim, or assuming old deadlines are still open do not benefit, since a new federal claim would run into the preemption ruling affirmed in January 2023 and most limitations periods expired years ago.
How do I check whether any Zofran option remains for me?
Have an attorney review your specific facts for any remaining state-law option, including whether rules pausing the clock for minors extend your deadline in your state. Do not spend money or energy assuming a new Zofran case has realistic prospects, and if your concern is a different drug, check that litigation's own deadlines instead, since the landscape differs by drug.